**Supplemental Materials**

**Supplemental Table 1.** Adverse events observed and adjudicated as possibly, probably or definitely related to therapy (n = 19).

|  |  |
| --- | --- |
|  | **CTCAE 3.0 Toxicity Grade** |
|  | **1** | **2** | **3** | **4** | **3/4** |
| **Hematologic Adverse Events** |  |  |  |  |  |
|      Hemoglobin | 1 (5.3%) | 1 (5.3%) | 0 | 0 | 0 |
|   |   |   |   |   |   |
| **Non-Hematologic Adverse Events** |  |  |  |  |  |
|      Fatigue | 6 (31.6%) | 2 (10.5%) | 0 | 0 | 0 |
|      Pain | 5 (26.3%) | 2 (10.5%) | 0 | 0 | 0 |
|      Nausea | 3 (15.8%) | 2 (10.5%)  | 0 | 0 | 0 |
|  AST-SGOT | 2 (10.5%) | 0 | 1 (5.3%) | 0 | 1 (5.3%) |
|      Hypophosphatemia | 1 (5.3%)  | 2 (10.5%)  | 0 | 0 | 0 |
|      Bilirubin | 2 (10.5%)  | 1 (5.3%)  | 0 | 0 | 0 |
|      Alkaline Phosphatase | 3 (15.8%) | 0 | 0 | 0 | 0 |
|      Alopecia | 3 (15.8%) | 0 | 0 | 0 | 0 |
|  ALT-SGPT | 0 | 1 (5.3%) | 1 (5.3%) | 0 | 1 (5.3%) |
|      Lipase | 0 | 1 (5.3%)  | 1 (5.3%)  | 0 | 1 (5.3%)  |
|      Rash | 0 | 1 (5.3%)  | 1 (5.3%)  | 0 | 1 (5.3%)  |
|      Hyponatremia | 1 (5.3%)  | 0 | 1 (5.3%)  | 0 | 1 (5.3%)  |
|      Amylase | 0 | 2 (10.5%)  | 0 | 0 | 0 |
|      Hypoalbuminemia | 1 (5.3%)  | 1 (5.3%)  | 0 | 0 | 0 |
|      Anorexia | 2 (10.5%) | 0 | 0 | 0 | 0 |
|      Diarrhea | 2 (10.5%)  | 0 | 0 | 0 | 0 |
|      Skin – Other | 2 (10.5%)  | 0 | 0 | 0 | 0 |
|      Hepatic – Elevated pancreatic enzymes | 0 | 0 | 1 (5.3%)  | 0 | 1 (5.3%)  |
|      Constitutional – Appetite loss | 0 | 1 (5.3%)  | 0 | 0 | 0 |
|      Dyspepsia | 0 | 1 (5.3%)  | 0 | 0 | 0 |
|  Edema | 0 | 1 (5.3%) | 0 | 0 | 0 |
|      Ocular – Visual changes | 0 | 1 (5.3%) | 0 | 0 | 0 |
|      Pruritis | 0 | 1 (5.3%)  | 0 | 0 | 0 |
|      Bronchospasm | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|      Cardiac - Palpitations | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|  Constipation | 1 (5.3%) | 0 | 0 | 0 | 0 |
|      Dry Skin | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|      Fever without Neutropenia | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|      Hyperkalemia | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|  Hypocalcemia | 1 (5.3%) | 0 | 0 | 0 | 0 |
|      Insomnia | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|      Nail Changes | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|  Sensory Neuropathy | 1 (5.3%) | 0 | 0 | 0 | 0 |
|      Taste Disturbance | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|      Urinary Frequency | 1 (5.3%)  | 0 | 0 | 0 | 0 |
|      Urinary Incontinence | 1 (5.3%) | 0 | 0 | 0 | 0 |